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Objectives We sought to determine whether the introduction of these agents had altered the outcome of dilated cardiomy-
opathy (DC) in childhood.
Background Pediatric DC has a poor prognosis. Angiotensin-converting enzyme inhibitors (ACEIs) and beta-adrenergic recep-
tor blockers (BBs) improve survival in adults with DC, but their effectiveness in children has not been confirmed.
Methods We performed a single-institution retrospective review of all diagnosed cases of DC and related phenotypic vari-
ants between 1976 and 2005, with multivariate analysis of risk factors for the end point of death or cardiac
transplantation.
Results A total of 189 patients presented between January 1, 1976, and March 31, 2005. Forty-four patients died, 34 under-
went cardiac transplantation, and 10 were lost to follow-up during this period. The 2- and 5-year transplantation-free
survival rates for all patients were 63.6% (95% confidence interval [CI]: 56.4% to 70.8%) and 56.3% (95% CI:
48.5% to 64.1%), respectively. For patients treated with digoxin but neither an ACEI nor a BB (n  51), the
5-year transplantation free survival rate was 67.5% (95% CI: 53.5% to 82.0%) and for those treated with the
addition of an ACEI but no BB (n  65), the rate was 57.2% (95% CI: 43.6% to 69.4%) (p  NS). Combination
therapy with an ACEI and a BB (n  57) was not associated with an improvement in 5-year transplantation-free
survival (58.5%; 95% CI: 42.5% to 72.0%, p  NS). In multivariable analysis, presentation with a low left ventric-
ular ejection fraction increased the risk of death or transplantation, but the end point was not influenced by time
era or treatment strategy.
Conclusions DC in childhood has a high risk of death or the need for transplantation. Medical treatment has shifted toward
combination ACEI and BB therapy in the current era. Our retrospective data, however, suggest only a transient
survival advantage associated with the combined use of ACEI and BB over ACEI alone and no obvious or sus-
tained improvement in transplantation-free survival accompanying the change from digoxin-based medical
therapy. (J Am Coll Cardiol 2010;55:1377–84) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.059l
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ailated cardiomyopathies (DCs) are a heterogeneous group
f diseases linked by a common phenotype of cardiac
hamber dilation and impaired myocardial contractility (1).
lthough this phenotype is shared by children and adults,
he underlying etiologies and their outcomes differ. Isch-
mic DC is rare in children, whereas DC as part of a
eneralized myopathy is more common in children than in
dults. Overall, approximately two-thirds of childhood DC
s idiopathic in origin (2), although, increasingly, specific
bnormalities of sarcomeric, cytoskeletal, and sarcolemmal
rom the Cardiomyopathy and Heart Function Program, Labatt Family Heart
entre, University of Toronto Hospital for Sick Children, Toronto, Ontario, Canada.
he authors received support of a Pediatric Consultants creative professional activities
rant from the Hospital for Sick Children, Toronto.e
Manuscript received April 22, 2009; revised manuscript received October 13, 2009,
ccepted November 3, 2009.inkage proteins are being identified (3). The prognosis of
ediatric DC also differs from that of DC presenting in
dults. Survival in some subgroups seems to be better than
hat in adult cohorts (4), whereas in others, survival beyond
hildhood is rare. Importantly, and in contradistinction to
dult populations, there has been no clear trend toward
mprovement in survival over time (4–7). In general, phar-
acotherapy of pediatric DC has mirrored that of adult
C, with a transition from the almost exclusive use of
igoxin and diuretics to widespread use of angiotensin-
onverting enzyme inhibitors (ACEIs) in the 1980s (8,9)
nd second- and third-generation beta-adrenergic receptor
lockers (BBs) in the 1990s. Although there is compelling
vidence supporting the use of both ACEIs and BBs in
dults with heart failure of either ischemic or nonisch-
mic origin (9,10), it is not clear whether adopting the
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Treatment and Survival in Pediatric Dilated Cardiomyopathy March 30, 2010:1377–84use of these agents has improved
the prognosis of pediatric DC
(11).We therefore sought to assess
the impact of changing medical
therapy from a digoxin-based reg-
imen to a BB/ACEI-based regi-
men on the transplantation-free
survival of patients with DC in the
context of single-institution expe-
rience accumulated between 1976
and 2005.
Methods
Institutional research ethics board
approval was obtained.
Case ascertainment. All patients
n our institutional database diagnosed between January 1,
976, and March 31, 2005, with a recorded diagnosis com-
atible with DC based on echocardiographic, angiographic, or
adionuclide imaging criteria were retrospectively identified.
ll diagnostic terms representative of the primary cardiomy-
pathies (as defined by the World Health Organization clas-
ification [1]), except for hypertrophic cardiomyopathy, were
ncluded as search terms. Patients younger than 18 years of age
nd meeting phenotypic criteria of left ventricular (LV) cham-
er dilation with an LV basal short-axis dimension at end-
iastole greater than body surface area–defined upper normal
imits (12) and in later years institutional normative z-scores,
nd having a left ventricular ejection fraction (LVEF) of50%
ere included. When clinical or tissue diagnosis had been
ade, this was noted. Examination of all available clinical
ecords was performed, and cases were assigned to 1 of 6
tiologic groups: post-myocarditis, neuromuscular disease,
etabolic disease, post-anthracycline exposure, idiopathic di-
ated, and unclassified. The latter included those with LV
oncompaction, phenotypic restrictive cardiomyopathy with
ither coexisting LV dilation or decreased systolic function,
nd endocardial fibroelastosis in which LV dilation was part of
he phenotype.
In the special case of myocarditis, the diagnosis was
erified to have been made on the basis of any 1 of 3
etrospective criteria: 1) histopathologic findings at endo-
yocardial biopsy using the Dallas criteria (13) when
pplicable; 2) marginal histopathologic evidence of lympho-
ytic infiltrate with necrosis and/or fibrosis when the pre-
onderance of clinical evidence supported this diagnosis;
nd 3) a suggestive clinical picture with decreased LVEF
nd associated viral pathogen isolation from blood or
yocardial tissue by polymerase chain reaction or virus
solation. Because LV dilation is not seen universally at the
nset of myocarditis, the presence of an LVEF within
ormal range at diagnosis was not considered an exclusion-
ry criterion when there was independent evidence of
yocarditis, but an abnormal LVEF was nevertheless re-
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ACEI  angiotensin-
converting enzyme inhibitor
BB  beta-adrenergic
receptor blocker
CI  confidence interval
DC  dilated
cardiomyopathy
EF  ejection fraction
LV  left ventricular
LVEF  left ventricular
ejection fractionuired for these cases to be included. tPhenotypic hypertrophic cardiomyopathies were ex-
luded from this analysis. Also excluded were DCs in
ssociation with congenital structural heart disease, primary
rrhythmogenic cardiomyopathies, and tachycardia-induced
ardiomyopathies.
edical management. Because survival time was our pri-
ary end point, we defined the onset of disease for each
atient as being the day on which a verifiable diagnostic
tudy (usually an echocardiogram) with criteria fulfilled was
emonstrated. We did not include the reported duration of
ymptoms in establishing disease onset. Cardiac medica-
ions prescribed after diagnosis were recorded in the follow-
ng agent-defined classes: digoxin, ACEIs, and BBs. The
se of these medications was confirmed throughout the
ourse of follow-up by review of the clinical records at each
ollow-up contact. Maintenance of a particular agent class
or at least 2 months of continuous therapy or until death or
ransplantation was required to enter a treatment group.
atients treated with combination medical therapies or
erial addition of medications were classified according to
he medications used at their most recent recorded follow-
p, provided that at least 1 month of treatment was
ompleted on the respective regimen (destination treat-
ent). We prospectively designated 3 mutually exclusive
estination treatment subgroups: digoxin but no ACEI or
B, ACEI with or without digoxin, and BB and ACEI
ith or without digoxin. Diuretics were not regarded as a
efinitive therapy class for the purpose of this analysis.
Our medication dosing guidelines during the study pe-
iod were as follows: digoxin 5 to 10 g/kg/day with
ntermittent levels required for a target of 1.2 to 2.5 ng/l;
aptopril target dose between 2 and 3 mg/kg/day divided
very 8 h; enalapril target dose 0.3 to 0.6 mg/kg/day divided
very 12 h; carvedilol target dose 1 mg/kg/day divided every
2 h; metoprolol target dose 2 to 4 mg/kg/day divided every
2 h. Medications were routinely up-titrated over a period
f 2 to 4 weeks, with subsequent dose adjustment made on
he basis of hemodynamic tolerance and weight gain.
Once a treatment group was entered, continuation of
edical therapy and LVEF were ascertained through serial
linical follow-up, and the occurrence of death or cardiac
ransplantation was determined. Patients were censored
rom further survival analysis when or if they were lost to
linical follow-up or at age 18 years of age. Medication
ithdrawal for reasons of either intolerance or clinical
mprovement did not result in a patient being censored from
treatment group or survival analysis. In such cases,
reatment group was defined according to the medication
ast received.
ssessment of outcome. Follow-up data were attained up
o age 18 if this occurred at our institution or until August
, 2005, for the end point of death, transplantation, or
ontinued clinical follow-up, regardless of transplantation
isting. We did not determine the outcome of patients lost
o follow-up by our institution. To identify any possible
ime era–related effect that was independent of patient
c
i
p
p
2
D
a
P
p
d
W
t
K
t
a
a
C
i
m
i
g
A
s
p
c
g
i
c
R
C
T
t
4
u
p
a
w
a
f
r
c
c
r
t
b
f
c
(
r
t
e
p
gn
os
is
an
d
O
ut
co
m
es
in
1
8
9
P
at
ie
nt
s
ab
le
1
D
ia
gn
os
is
an
d
O
ut
co
m
es
in
1
8
9
P
at
ie
nt
s
A
ll
P
at
ie
nt
s
(N

1
8
9
)
M
yo
ca
rd
it
is
(n

3
7
)
Id
io
pa
th
ic
D
C
(n

9
8
)
U
nc
la
ss
ifi
ed
(n

2
4
)
A
nt
hr
ac
yc
lin
e
(n

6
)
N
eu
ro
m
us
cu
la
r
D
is
or
de
rs
(n

1
4
)
In
bo
rn
Er
ro
rs
of
M
et
ab
ol
is
m
(n

1
0
)
ed
ia
n
ag
e
at
di
ag
no
si
s,
yr
s
(I
Q
R
)
1
.0
(0
.5
–8
.0
)
1
.0
(0
.3
–4
.5
)
1
.0
(0
.3
–6
.5
)
2
.0
(0
.8
–6
.0
)
3
.0
(1
.1
–4
.5
)
1
4
.0
(1
2
.0
–1
6
.0
)
1
.0
(0
.8
–2
.0
)
al
e/
fe
m
al
e
1
0
3
/8
6
2
3
/1
4
4
5
/5
3
1
4
/1
0
4
/2
1
2
/2
5
:5
F
at
pr
es
en
ta
tio
n,
%
(m
ea
n

S
D
)
2
9

1
6
2
9

1
4
2
5

1
5
4
4

1
7
4
7

1
3
2
7

1
2
3
3

2
0
F
at
la
st
fo
llo
w
-u
p,
%
(m
ea
n

S
D
)
3
9

2
1
4
8

2
2
3
5

1
9
5
3

1
5
5
3

1
4
2
5

1
3
2
2

1
0
ol
lo
w
-u
p,
m
on
th
s
(m
ea
n

S
D
)
4
3
.8

5
1
.5
4
8
.3

5
4
.4
4
3
.9

5
4
.0
5
0
.5

4
8
.4
6
1
.0

4
4
.5
2
4
.6

3
9
.1
2
9
.1

4
0
.2
o.
lo
st
to
fo
llo
w
-u
p
1
0
2
4
1
0
2
1
o.
of
de
at
hs
(p
re
-tr
an
sp
la
nt
at
io
n)
*
4
4
6
2
3
1
1
7
6
o.
of
ca
rd
ia
c
tr
an
sp
la
nt
at
io
ns
3
4
2
2
2
6
0
3
1
ct
ua
ri
al
tr
an
sp
la
nt
at
io
n-
fr
ee
su
rv
iv
al
ra
te
,%
(9
5
%
C
I)
1
yr
7
1
.3
%
(6
4
.6
%
–7
7
.9
%
)
8
6
.0
%
(7
4
.3
%
–9
7
.3
%
)
6
9
.7
%
(6
0
.4
%
–7
8
.9
%
)
8
7
.1
%
(7
4
.2
%
–1
0
0
%
)
5
5
.3
%
(2
8
.4
%
–8
2
.1
%
)
6
9
.2
%
(4
4
.1
%
–9
4
.3
%
)
2
yr
s
6
3
.6
(5
6
.4
–7
0
.8
)
8
2
.1
(6
9
.0
–9
5
.3
)
5
6
.6
(4
6
.3
–6
6
.9
)
7
7
.4
(5
9
.9
–9
4
.9
)
3
9
.5
(1
2
.8
–6
6
.2
)
5
1
.9
%
(2
3
.9
%
–7
9
.9
%
)
5
yr
s
5
6
.3
%
(4
8
.5
%
–6
4
.1
%
)
7
7
.8
%
(6
2
.9
%
–9
2
.7
%
)
5
2
.0
%
(4
1
.3
%
–6
2
.6
%
)
7
0
.4
%
(4
9
.7
%
–9
1
.1
%
)
2
6
.3
%
(0
–5
3
.8
%
)
3
2
.5
%
(5
.3
%
–6
0
.4
%
)
1
0
yr
s
5
0
.4
%
(4
1
.5
%
–5
9
.4
%
)
7
7
.8
%
(6
2
.9
%
–9
2
.7
%
)
4
3
.7
%
(3
1
.1
%
–5
6
.3
%
)
6
0
.3
%
(3
4
.3
%
–8
5
.7
%
)
2
6
.3
%
(0
–5
3
.8
%
)
3
2
.5
%
(5
.3
%
–6
0
.4
%
)
se
s
of
di
la
te
d
ca
rd
io
m
yo
pa
th
y
(D
C
)
w
er
e
de
te
rm
in
ed
fr
om
cl
in
ic
al
re
co
rd
s.
A
ct
ua
ri
al
su
rv
iv
al
is
ba
se
d
on
K
ap
la
n-
M
ei
er
es
tim
at
es
at
1
,
2
,
5
,
an
d
1
0
ye
ar
s
af
te
r
di
ag
no
si
s
of
D
C
.
*N
o.
of
de
at
hs
do
es
no
t
in
cl
ud
e
pa
ti
en
ts
w
ho
un
de
rw
en
t
tr
an
sp
la
nt
at
io
n
an
d
la
te
r
(n

6
).

co
nfi
de
nc
e
in
te
rv
al
;E
F

ej
ec
tio
n
fr
ac
tio
n;
IQ
R

in
te
rq
ua
rt
ile
ra
ng
e.
1379JACC Vol. 55, No. 13, 2010 Kantor et al.
March 30, 2010:1377–84 Treatment and Survival in Pediatric Dilated Cardiomyopathyharacteristics, we conducted analyses of the cohort divided
nto time quartiles of 7 years (9.7 years for the most recent
eriod) as well as an analysis of survival probability, com-
aring the time era of 1976 to 1989 with that of 1990 to
005.
ata analysis. Analysis was performed using commercially
vailable software (SAS Institute, Cary, North Carolina;
rism 4, GraphPad Corp., San Diego, California). Com-
arisons among groups for normally distributed parametric
ata used the Student t test. For skewed data, the Kruskal-
allis test was used. Nonparametric data were analyzed using
he chi-square test. Survival analysis was performed using the
aplan-Meier method, with post hoc testing using the Scheffé
est when a specific hypothesis existed. For between-group
nalysis in the survival probability distributions, we did not
djust the p value when performing multiple comparisons.
ox proportional hazard analysis was performed to assess
ndependent predictors of outcome in a multivariable
odel. Data are expressed as mean  SD or median with
nterquartile range, and 95% confidence interval (CIs) are
iven where appropriate.
ssumptions. Our analysis makes certain statistical as-
umptions, for example, that there was an equivalent pro-
ensity to treat any given etiologic group with any and all
ombinations of medical therapy available at the time, and
eneral assumptions regarding survival analysis also pertain,
ncluding that the presence of a proportional hazard remains
onstant throughout the survival analysis.
esults
haracteristics of the patients identified are listed in Table 1.
here were 189 patients included in this analysis from 1976
o March 31, 2005. By the conclusion of the study period,
4 patients (23%) were verified to have died without
ndergoing transplantation, and 34 (18%) underwent trans-
lantation. All of the remaining 111 patients were censored
t their last documented follow-up visit at our institution,
ith 15 (8%) patients transferred to an adult cardiologist at
ge 18. Another 36 (19%) patients were discharged from
ollow-up with complete clinical and echocardiographic
ecovery. Of the remainder, 6 (3%) were followed at other
enters, 43 (23%) were currently in active follow-up at our
enter, and 10 (5%) were censored without information
egarding further care (lost to follow-up).
The median age at presentation was 1.0 years (interquar-
ile range 0.5 to 8.0 years) and did not differ significantly
etween time quartiles (Fig. 1B). The overall male-to-
emale ratio was 1.2:1. Cardiac transplantation as an out-
ome became more common in the latter period of study
after 1989), with 26% of patients from that time onward
eceiving a transplant until August 2005. Death after cardiac
ransplantation occurred in 6 (17.6%) of these patients.
Diagnostic groups identified are shown in Table 1. As
xpected, idiopathic DC was the largest of these. The
revalence of each of the diagnoses showed no significant Di
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Treatment and Survival in Pediatric Dilated Cardiomyopathy March 30, 2010:1377–84ifference between time quartiles by chi-square analysis
Fig. 1B), suggesting that newer molecular diagnostic tech-
iques did not have a significant impact on the diagnostic
ategorization in our recent institutional experience.
urvival with cardiomyopathy. Overall, we observed an
mportant early risk of death or transplantation in our
atient population, with actuarial freedom from this com-
osite outcome of 71.3% (95% CI: 64.6% to 77.9%) at 12
onths post-diagnosis and a further steady decrease to 56%
t 5 years post-diagnosis (Table 1). The importance of the
ate of diagnosis was assessed by survival analysis using the
aplan-Meier method for cohorts segregated by time era.
hese were designated as diagnosis occurring between 1976
nd 1989 (n  60) and 1990 and 2005 (n  129),
orresponding roughly to the pre- and post-transplantation
ra at our institution. Survival curves for these time eras
A
B
Figure 1 Trends in Diagnosis and Medication Adoption for Pedi
(A) Histogram distribution of medication use by year of diagnosis. Medication use
mutually exclusive in this figure. (B) Selected cohort demographics, segregated ac
the most common diagnoses (myocarditis and idiopathic etiologies). The percenta
tile. There was no significant difference in the frequency of any of the 6 etiologic g
pathic: p  0.88). Age distribution did not differ in each time quartile (Kruskal-Wa
converting enzyme inhibitor; EF  ejection fraction; IQR  interquartile range.ere very similar, with no statistical difference for wransplantation-free survival (log-rank test: p  0.65, data
ot shown).
URVIVAL BY TREATMENT STRATEGY. All but 13 patients in
he cohort had received oral maintenance therapy with 1
f the agents in question. Treatment was maintained in all
atients until the defined end point of death or transplan-
ation was reached. Treatment was discontinued in 6
atients while in follow-up because of improved or normal-
zed systolic function. For the remaining 170 patients
96.5% of whom commenced oral maintenance therapy),
edication use continued until death, transplantation, or
he last recorded follow-up assessment. Figure 1 demon-
trates the frequency of medication choices according to
ear of diagnosis. An ACEI as a therapy was introduced in
his institution in the early 1980s and became more preva-
ent in the 1990s. Of those receiving an ACEI, captopril
Dilated Cardiomyopathy From 1976 to 2005
ts treatment at last follow-up, death, or transplantation, and categories are not
g to 4 time quartiles: time quartile etiologic group incidences are indicated for
all patients who received a particular medication are segregated by time quar-
over the 4 time quartiles (chi-square test for trend; myocarditis: p  0.14, idio-
t: p  0.18). ACE  angiotensin-converting enzyme; ACEI  angiotensin-atric
reflec
cordin
ges of
roups
llis tesas used in 47% (n  55), enalapril in 37% (n  43), and
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March 30, 2010:1377–84 Treatment and Survival in Pediatric Dilated Cardiomyopathyamipril in 6% (n 8). BBs were not used in our experience
ntil 1991, and then their use became more frequent. Of
hose patients receiving a BB, metoprolol (33%, n 19) and
arvedilol (61%, n  35) were used in the majority. We
oted only 1 patient who was treated with a BB while not
eing treated concurrently with an ACEI.
With regard to changes in patient characteristics with
ime (Fig. 1), we did note some variance in the echocardio-
raphic severity at presentation, with those in time quartile
(1983 to 1989) having a somewhat higher LVEF at
resentation than those in quartile 4 (1996 to 2005) (p 
.03; 1-way analysis of variance, Bonferroni post-test.). We
id not find any interquartile differences in the LVEF at the
ast recorded follow-up visit (including that before death or
ransplantation): this LVEF was significantly higher than
he LVEF at presentation in every quartile (data not
hown). The prevalence ratio of the diagnoses of myocar-
itis to idiopathic DC showed no significant trend with
ime by chi-square analysis (Fig. 1).
By comparing the transplantation-free survival course of
ll patients as a function of destination treatment strategy
Fig. 2), we were unable to demonstrate any survival
dvantage at 60 months for those treated with an ACEI or
combination of an ACEI and BB over treatment with
igoxin alone. Careful inspection of the early hazard phase
or mortality or transplantation did, however, demonstrate a
% survival advantage with the combination of ACEI and
B over ACEI alone by 11 months of therapy, and a 14%
dvantage at 21 months (hazard ratio: 1.49). Thereafter,
owever, the survival curves converged, so that by 60
onths, no advantage was evident.
We did note a group of 13 patients in whom no oral
aintenance therapy was attained. For the most part, as
Figure 2 Transplantation-Free Survival
Probability as a Function of Treatment Strategy
Three distinct treatment subgroups were identified prospectively: 1) digoxin,
but no angiotensin-converting enzyme (ACE) inhibitor or beta-blocker; 2) ACE
inhibitor with or without digoxin; and 3) beta-blocker and ACE inhibitor, with or
without digoxin. There was a significant difference between the curves plotted
(log-rank test: p  0.01), which is attributable to the survival disadvantage of
the no oral maintenance therapy group versus digoxin.alotted in Figure 2, these 13 patients progressed to death or
ransplantation quite rapidly, with only 30.5% (95% CI: 5%
o 56%) surviving longer than 12 months. We found that for
ll treatment groups, the predominant hazard phase was
vident in the first 24 months after clinical detection and
hat there was relatively less attrition after 24 months of
ollow-up.
URVIVAL BY DISEASE ETIOLOGY/PHENOTYPE AND EF AT
IAGNOSIS. There was a significant difference in survival
etween the 6 etiologic groups (Fig. 3). Patients with a
iagnosis of myocarditis had a 5-year survival probability of
8% versus 52% for those with idiopathic DC (p  0.03;
cheffé test). Patients with either neuromuscular or meta-
olic diseases fared the worst (5-year survival rate of 26%
nd 33%, respectively). Although all patients with
nthracycline-induced cardiomyopathy survived, the num-
ers were too small to draw any conclusion. Interestingly,
omparing the initial and last recorded LVEF in all patient
roups other than those with neuromuscular/metabolic
isease (Table 1), an overall improvement was noted,
ncluding for those patients who died or required a heart
ransplantation.
CHOCARDIOGRAPHIC SEVERITY AT PRESENTATION. A
igher LVEF at diagnosis did confer a survival advantage.
n Figure 4, the survival probability based on the LVEF at
iagnosis is displayed with patients segregated into the
ertiles of 35% (nominally mild dysfunction), 20%
severe dysfunction), or in between these 2 tertiles (moder-
Figure 3 Transplantation-Free Survival
Measured by Etiologic/Phenotypic Group
Five of the etiologic groups are plotted, those with anthracycline cardiotoxicity
being omitted from the plot due to small numbers. Survival probability for most
patients decreased dramatically in the first 24 months. There was, however, a
significant difference between the groups indicated by the log-rank test (p 
0.002). Post hoc testing revealed a significant difference in survival between
those with myocarditis (5-year survival rate of 78%) and those with idiopathic
cardiomyopathy (5-year survival rate of 52%) by the Scheffé test (p  0.03).
DCM  dilated cardiomyopathy.te dysfunction). Patients with an EF at diagnosis of 20%
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Treatment and Survival in Pediatric Dilated Cardiomyopathy March 30, 2010:1377–84ad a far less favorable survival probability of 37% at 5 years
ost-diagnosis (p  0.01) than the remainder of patients.
isk factors in a multivariable model. Our multivariable
nalysis considered several putative risk factors for death or
ardiac transplantation (Table 2). Age at presentation did
ot confer significant risk, although there was a trend
oward increased risk with increasing age. A lower EF at
resentation, however, substantially increased the risk of
his composite outcome measure. The incremental risk was
alculated to increase by 35% for every 10% decrease in
VEF at presentation. Regarding diagnosis, those with
yocarditis did significantly better in the multivariable
odel than those with idiopathic DC (hazard ratio: 0.41),
nd patients with a neuromuscular disease diagnosis tended
o do more poorly than the idiopathic group. With regard to
reatment strategy, those patients who were not started on
ny of the 3 oral maintenance medications (digoxin, ACEI,
r BB) were at substantially greater risk. An analysis of these
3 patients indicated that most of those in this group either
ied or underwent transplantation soon after their diagnosis
nd were too unstable to be weaned off inotropic agents and
ommence oral therapy. In the entire cohort, we once again
ound that the addition of an ACEI or combination therapy
ith an ACEI and BB did not decrease the risk of death or
ransplantation by multivariable analysis.
iscussion
ediatric DC continues to pose a major clinical challenge,
ith mortality greatly exceeding most other forms of heart
isease in children (14). Although our understanding of the
tiology and pathophysiology of DC has undoubtedly im-
roved, the response to therapeutic algorithms successfully
pplied to treat DC in adults remains uncertain. Similar to
he management of advanced heart failure in adult patients,
Figure 4 Transplantation-Free Survival
Measured by EF at Diagnosis
Ejection fraction (EF) at diagnosis was segregated into tertiles of 35%,
between 20% and 35%, and 20%. Patients who had an EF 20% at diagno-
sis have a significantly less favorable survival probability than others over a
5-year period (37%) (p  0.01).ransplantation is of proven benefit (11), and, accordingly,
rechanical circulatory support is increasingly promoted in
hildren as a bridge to transplantation (15) or even to
ecovery (16). Similarly, the entire portfolio of medical
herapies proven effective in adults is available to treat
hildren, but the response to these medications is much less
ell understood. In the current study, we documented the
utcomes of pediatric DC and identified risk factors for
eath or transplantation. Our data, however, raise questions
s to whether evolving pharmacologic treatments for heart
ailure in these patients are independently improving
urvival.
Several retrospective studies have reported outcomes for
hildren with DC in cohorts between the 1970s and the
990s (4–7,11). These have all been relatively small and
arefully selected cohorts with specific phenotypic features
nd have quoted widely divergent survival rates. Our data
epresent the largest retrospective study comparing the
mpact of medical therapies as a risk factor for outcome in
ediatric DC. Overall, our patients had a 10-year freedom
rom death rate of 70%, which is consistent with multi-
nstitutional registry data. The National Australian Child-
ood Cardiomyopathy Study, representing outcomes of
hildren younger than age 11 years between 1987 and 1996,
ound a 5-year transplantation-free survival rate of 63%
17). In that study, patients presenting as a sudden unex-
ected death were included, and patients with inborn errors
f metabolism or progressive neuromuscular disease were
pecifically excluded. The North American Pediatric Car-
iomyopathy Registry, which excludes patients with
nthracycline- and neuromuscular disease-related DCs,
ited a similar 5-year absolute survival rate of 70% and
ransplantation-free survival rate of 55% in their most recent
eport (18). Furthermore, as in the current study, early age
t presentation, a low z-score of fractional shortening, and
ultivariable Probability/Hazardnalysis for Death or Transpl ntationTable 2 Mul ivar able Probabil ty/HazardAnalysis for Death or Transplantation
Parameter
Chi-Square
Test p Value
Hazard
Ratio 95% CI
Presenting features
Age 3.09 0.08 1.04 0.99–1.09
Ejection fraction 15.16 0.01 0.66 0.53–0.81
Diagnosis
Anthracycline toxicity 2.60 0.10 0.37 0.12–1.23
Myocarditis 4.87 0.02 0.41 0.19–0.91
Unclassified 0.19 0.66 0.63 0.08–4.89
Metabolic disease 0.67 0.41 1.42 0.61–3.28
Neuromuscular disease 3.30 0.07 2.27 0.94–5.50
Treatment
No oral maintenance
therapy
15.26 0.01 6.17 2.48–15.38
Digoxin only 1.59 0.20 1.59 0.77–3.28
ACEI  digoxin 0.60 0.44 1.27 0.69–2.33
he risk of death or transplantation was found to decrease by 35% for every 10% increase in
jection fraction at presentation in this model. Diagnosis group hazard ratio is expressed with
eference to idiopathic dilated cardiomyopathy. Treatment group hazard ratio is expressed with
eference to combined therapy with ACEI and beta-blocker, with or without digoxin.
ACEI  angiotensin-converting enzyme inhibitor; CI  confidence interval.
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March 30, 2010:1377–84 Treatment and Survival in Pediatric Dilated Cardiomyopathytiologies other than acute myocarditis were identified as
isk factors in the North American Pediatric Cardiomyop-
thy Registry cohort. In this respect, it is noteworthy that
atients with a metabolic disease or with a neuromuscular
isease in our study could not be determined retrospectively
o have died of their cardiomyopathy solely, and it may be
ssumed that their neurologic or metabolic status contrib-
ted to some degree.
Although registry data include much larger numbers of
atients than can be expected in single-center studies, the
ata collection has been relatively brief and neither the
ational Australian Childhood Cardiomyopathy Study data
or the North American Pediatric Cardiomyopathy Regis-
ry data analyzed the effect of drug therapies on outcomes.
ur data span a greater time period and report outcomes
cross a wider etiologic range than either of these reports. In
ur cohort, there has been no clear improvement in survival
robability when the 30-year period of analysis is divided
nto earlier and later 15-year eras. Furthermore, there was
o survival advantage associated with the use of ACEIs or
Bs. Although EF tended to improve with time, both for
he group as a whole and for many of the phenotypic
ategories, this trend may reflect the attrition of cases with
ery poor function to death or transplantation as time
rogresses. Some degree of spontaneous improvement
eems to be possible in pediatric DC, however; a trend
oward improving EF was also noted by Canter et al. (19) in
heir recently reported placebo-controlled trial of carvedilol
n selected children with moderate heart failure. In the
anter et al. (19) study, children with structural congenital
eart disease or cardiomyopathy randomized to therapy
ith carvedilol (in addition to the usual treatment) did show
modest improvement in EF, but no improvement in a
omposite score of clinical status over a 6-month period of
reatment. With the exception of these data, the efficacy of
edical treatments for heart failure in pediatric populations
as not been rigorously assessed prospectively. Of relevance
o our study, Lewis and Chabot (20) reviewed the institu-
ional experience with 81 patients in the era before carve-
ilol and found a marginal improvement in survival on
nivariate analysis for patients treated with an ACEI
xtending as long as 2 years post-diagnosis. However, Burch
t al. (5) found no reduction in the risk of death or cardiac
ransplantation in their retrospective series of 61 patients
reated with captopril.
It is important to note that the failure of BB and ACEI
o affect long-term survival in pediatric DC in our experi-
nce does not imply a lack of efficacy of these medications.
tatistically significant efficacy in a controlled setting with
arge numbers of carefully selected patients has already been
emonstrated in numerous trials in adults with heart failure.
ather, we believe that our data highlight a lack of overall
linical effectiveness of these treatments in a real-world
ituation when faced with the range of aggressive disease
henotypes seen in pediatric patients with symptomatic
C. This is reinforced by the observations made in our btudy that there is an important early hazard phase for death
fter initial presentation and that the presenting severity of
V dysfunction strongly predicts outcome, implying that an
rreversible loss of myocardial function has already been
ustained by the time many patients come to clinical
ttention.
tudy limitations. Although this study attempts to deter-
ine differences resulting from a change in treatment
pproach, the era has also changed and along with it the
vailability of surgical mechanical support and transplanta-
ion therapies. The propensity to select transplantation
uring the latter period (1990 to 2005) may also have
hanged. Other confounding factors affecting disease detec-
ion and outcome may also obscure either a beneficial or
ven a deleterious effect of current medical treatment
hoices.
Our institution has been a quaternary referral center for
he Province of Ontario throughout the 30-year period and,
herefore, our case severity and representation are subject to
eferral bias. Indeed, the relatively smaller cohort size from
976 to 1989 may reflect changing diagnostic accuracy and
eferral patterns during that time period.
Our dataset is limited in size compared with those of
arge prospective, randomized trials of carvedilol and other
edical therapies. We were able to calculate, based on the
ethod of Machin et al. (21), that that the transient trend
oward a survival benefit that we observed with the com-
ined BB and ACEI therapy versus treatment with an
CEI alone between 11 and 24 months after diagnosis
ould have required a 25.9% difference in survival at 2 years
fter diagnosis to reach significance in this cohort. Although
ot statistically significant in this cohort, the actual observed
urvival advantage would have proved significant with a
ower of 0.8 if the groups in question had contained 776
ubjects equally apportioned.
However, it is unlikely that a large randomized trial of
ny one therapy could now be conducted prospectively,
iven the relative rarity of pediatric DC and the established
ractice patterns that have developed with time.
Our dataset must be interpreted with the same caution as
hose of all retrospective or registry-based studies. With
egard to treatments given, we carefully documented the
ontinued use of medical treatments, but not the variations
n their dosage that occurred with physical growth and
hange in symptom status. This information was considered
o be difficult to interpret because there were (and are) few
lear guidelines for optimal dosing of ACEIs and BBs in
hildren. Furthermore, patient weight and adverse symp-
oms were not consistently recorded in the medical records
f all patients.
The analysis is intrinsically complicated by variations in
edical treatment combinations given to patients because,
heoretically, a patient may have been classified to destina-
ion therapy in a group, which did not reflect their predom-
nant medication regimen throughout their experience. We
elieve that these limitations are largely offset by the ability
t
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Treatment and Survival in Pediatric Dilated Cardiomyopathy March 30, 2010:1377–84o gain insight into the eventual efficacy of therapy based on
ntention to treat and in real-world, uncontrolled circum-
tances over a prolonged period.
onclusions
hildren with DC vary considerably in underlying cause,
everity, and age at presentation. These factors have a major
ole in determining survival, which remains relatively poor
nd has changed little in the past 30 years. We identified
ower EF at presentation and the absence of acute myocar-
itis as primary risk factors for poor outcome. Additionally,
e excluded a statistically significant survival benefit from
ore recently adopted medical therapies (within the con-
traints of the cohort size already noted). According to our
xperience, the outcome of pediatric DC is more likely to be
etermined by the etiology of the disease than the choice of
edical therapy applied within the current framework of
eart failure management options. It is important to note,
owever, that the undefined nature of idiopathic and un-
lassified DC presents the possibility that, in the future,
pecific molecular diagnosis may reveal subgroups of pa-
ients who will in fact respond well to specific medical
herapies.
Further prospective study, including completion of ran-
omized clinical trials in well-defined, etiology-specific
ubgroups, will be required to determine the true efficacy of
ny particular drug with regard to morbidity and mortality.
t present, cardiac transplantation remains the most viable
ong-term option for patients with severe symptomatic
isease at presentation.
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